<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We investigated whether the antiproteinuric effect of the direct renin inhibitor <z:chebi fb="0" ids="601027">aliskiren</z:chebi> is comparable to that of <z:chebi fb="0" ids="5959">irbesartan</z:chebi> and the effect of the combination </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: This was a double-blind, randomized, crossover trial </plain></SENT>
<SENT sid="2" pm="."><plain>After a 1-month washout period, 26 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and <z:mp ids='MP_0002871'>albuminuria</z:mp> (&gt;100 mg/day) were randomly assigned to four 2-month treatment periods in random order with placebo, 300 mg <z:chebi fb="0" ids="601027">aliskiren</z:chebi> once daily, 300 mg <z:chebi fb="0" ids="5959">irbesartan</z:chebi> once daily, or the combination using identical doses </plain></SENT>
<SENT sid="3" pm="."><plain>Patients received <z:chebi fb="0" ids="47426">furosemide</z:chebi> in a stable dose throughout the study </plain></SENT>
<SENT sid="4" pm="."><plain>The primary end point was a change in <z:mp ids='MP_0002871'>albuminuria</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Secondary measures included change in 24-h blood pressure and glomerular filtration rate (GFR) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Placebo geometric mean <z:mp ids='MP_0002871'>albuminuria</z:mp> was 258 mg/day (range 84-2,361), mean +/- SD 24-h blood pressure was 140/73 +/- 15/8 mmHg, and GFR was 89 +/- 27 ml/min per 1.73 m(2) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="601027">Aliskiren</z:chebi> treatment reduced <z:mp ids='MP_0002871'>albuminuria</z:mp> by 48% (95% CI 27-62) compared with placebo (P &lt; 0.001), not significantly different from the 58% (42-79) reduction with <z:chebi fb="0" ids="5959">irbesartan</z:chebi> treatment (P &lt; 0.001 vs. placebo) </plain></SENT>
<SENT sid="8" pm="."><plain>Combination treatment reduced <z:mp ids='MP_0002871'>albuminuria</z:mp> by 71% (59-79), more than either monotherapy (P &lt; 0.001 and P = 0.028) </plain></SENT>
<SENT sid="9" pm="."><plain>Fractional clearances of albumin were significantly reduced (46, 56, and 67% reduction vs. placebo) </plain></SENT>
<SENT sid="10" pm="."><plain>Twenty-four-hour blood pressure was reduced 3/4 mmHg by <z:chebi fb="0" ids="601027">aliskiren</z:chebi> (NS/P = 0.009), 12/5 mmHg by <z:chebi fb="0" ids="5959">irbesartan</z:chebi> (P &lt; 0.001/P = 0.002), and 10/6 mmHg by the combination (P = 0.001/P &lt; 0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>GFR was significantly reduced 4.6 (95% CI 0.3-8.8) ml/min per 1.73 m(2) by <z:chebi fb="0" ids="601027">aliskiren</z:chebi>, 8.0 (3.6-12.3) ml/min per 1.73 m(2) by <z:chebi fb="0" ids="5959">irbesartan</z:chebi>, and 11.7 (7.4-15.9) ml/min per 1.73 m(2) by the combination </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: The combination of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> and <z:chebi fb="0" ids="5959">irbesartan</z:chebi> is more antiproteinuric in type 2 diabetic patients with <z:mp ids='MP_0002871'>albuminuria</z:mp> than monotherapy </plain></SENT>
</text></document>